Patents by Inventor Seong Jun Yoon

Seong Jun Yoon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250134851
    Abstract: Described is compound that can be used as an alternative to botulinum neurotoxin and a preparation method thereof, and more specifically, the present invention relates to a myricetin acetyl derivative and a preparation method thereof, wherein the myricetin acetyl derivative has significantly improved stability, including in-vivo stability, and has the ability to inhibit SNARE complex formation, and as a result, to inhibit acetylcholine release.
    Type: Application
    Filed: August 24, 2022
    Publication date: May 1, 2025
    Inventors: Seong Jun Yoon, An Sung Kwon, Soo Youn Jun, Ji Sung Park, Seon Ho Park, Sang Hyeon Kang
  • Patent number: 12280081
    Abstract: A composition for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes a Siphoviridae bacteriophage (Bac-FRP-5) having an ability to lyse the enterotoxigenic Bacteroides fragilis cells and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes administering to a subject a Siphoviridae bacteriophage and lysing the enterotoxigenic Bacteroides fragilis cells by the Siphoviridae bacteriophage.
    Type: Grant
    Filed: October 31, 2023
    Date of Patent: April 22, 2025
    Assignee: iNtRON Biotechnology, Inc.
    Inventors: Seong Jun Yoon, Jee Soo Son, In Hwang Kim, Hyoung Rok Paik, Eun Kyoung Oh, Geun Woo Lee, Soo Youn Jun, Sang Hyeon Kang
  • Patent number: 12274721
    Abstract: A composition for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes a Siphoviridae bacteriophage (Bac-FRP-4) having an ability to lyse the enterotoxigenic Bacteroides fragilis cells and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes administering to a subject a Siphoviridae bacteriophage and lysing the enterotoxigenic Bacteroides fragilis cells by the Siphoviridae bacteriophage.
    Type: Grant
    Filed: October 31, 2023
    Date of Patent: April 15, 2025
    Assignee: iNtRON Biotechnology, Inc.
    Inventors: Seong Jun Yoon, Jee Soo Son, In Hwang Kim, Hyoung Rok Paik, Eun Kyoung Oh, Soo Youn Jun, Sang Hyeon Kang
  • Patent number: 12263196
    Abstract: A composition for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes a Siphoviridae bacteriophage (Bac-FRP-3) having an ability to lyse the enterotoxigenic Bacteroides fragilis cells and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes administering to a subject a Siphoviridae bacteriophage and lysing the enterotoxigenic Bacteroides fragilis cells by the Siphoviridae bacteriophage.
    Type: Grant
    Filed: October 19, 2023
    Date of Patent: April 1, 2025
    Assignee: iNtRON Biotechnology, Inc.
    Inventors: Seong Jun Yoon, Jee Soo Son, In Hwang Kim, Hyoung Rok Paik, Eun Kyoung Oh, Soo Youn Jun, Sang Hyeon Kang
  • Publication number: 20240390483
    Abstract: The present invention is related to a mucosal mRNA vaccine. More specifically, the present invention relates to novel mucosal mRNA vaccine based on a peptide-conjugated, mRNA loaded nanoparticle with enhanced vaccine efficacy, and a method of preparing the same.
    Type: Application
    Filed: September 9, 2022
    Publication date: November 28, 2024
    Inventors: Seong Jun YOON, Soo Youn JUN, Ji Sung PARK, Sang Hyeon KANG
  • Publication number: 20240366695
    Abstract: A composition for treating an infection or disease caused by a pathogenic Escherichia coli includes a Myoviridae bacteriophage Esc-COP-23 having an ability to lyse the pathogenic Escherichia coli and a pharmaceutically acceptable carrier. A method for treating an infection or disease caused by a pathogenic Escherichia coli includes administering to a subject a Myoviridae bacteriophage and lysing the pathogenic Escherichia coli by the Myoviridae bacteriophage.
    Type: Application
    Filed: July 14, 2024
    Publication date: November 7, 2024
    Inventors: Seong Jun YOON, Jee Soo SON, In Hwang KIM, Hyoung Rok PAIK, Hyun Joo IM, Beom Seok KIM, Eun Kyoung OH, Soo Youn JUN, Sang Hyeon KANG
  • Patent number: 12114664
    Abstract: The present invention relates to a Siphoviridae bacteriophage STP-2 (Accession number: KCTC 12853BP) isolated from nature and characterized by having the ability to destroy Salmonella Typhimurium and having a genome represented by SEQ ID NO:1; and to a method for preventing and treating diseases caused by Salmonella Typhimurium using Siphoviridae bacteriophage STP-2 containing the same as an active ingredient.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: October 15, 2024
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Soo Youn Jun, Jee Soo Son, Hyoun Rok Paik, Beom Seok Kim, Sang Hyeon Kang
  • Patent number: 11970700
    Abstract: The present invention relates to an intracellular expression enhancing genetic element, which enhances the intracellular expression of target protein encoded in RNA therapeutics such as mRNA vaccines and RNA medicines. In more detail, the present invention relates to the RNA molecule which has the genetic element capable of enhancing the intracellular expression of target protein encoded in RNA therapeutics delivered into cells; the plasmid used to synthesize the RNA molecule having the genetic element “E3”; the method for synthesizing RNA molecule having the genetic element “E3” using the plasmid and utilizing the synthesized RNA molecule as RNA therapeutics.
    Type: Grant
    Filed: December 13, 2022
    Date of Patent: April 30, 2024
    Assignee: Intron Biotechnology, Inc.
    Inventors: Seong Jun Yoon, An Sung Kwon, Se Hwan Kim, Sang Hyeon Kang
  • Publication number: 20240050499
    Abstract: A composition for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes a Siphoviridae bacteriophage (Bac-FRP-4) having an ability to lyse the enterotoxigenic Bacteroides fragilis cells and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes administering to a subject a Siphoviridae bacteriophage and lysing the enterotoxigenic Bacteroides fragilis cells by the Siphoviridae bacteriophage.
    Type: Application
    Filed: October 31, 2023
    Publication date: February 15, 2024
    Inventors: Seong Jun YOON, Jee Soo SON, In Hwang KIM, Hyoung Rok PAIK, Eun Kyoung OH, Soo Youn JUN, Sang Hyeon KANG
  • Publication number: 20240050500
    Abstract: A composition for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes a Siphoviridae bacteriophage (Bac-FRP-5) having an ability to lyse the enterotoxigenic Bacteroides fragilis cells and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes administering to a subject a Siphoviridae bacteriophage and lysing the enterotoxigenic Bacteroides fragilis cells by the Siphoviridae bacteriophage.
    Type: Application
    Filed: October 31, 2023
    Publication date: February 15, 2024
    Inventors: Seong Jun YOON, Jee Soo SON, In Hwang KIM, Hyoung Rok PAIK, Eun Kyoung OH, Geun Woo LEE, Soo Youn JUN, Sang Hyeon KANG
  • Publication number: 20240041958
    Abstract: A composition for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes a Siphoviridae bacteriophage (Bac-FRP-3) having an ability to lyse the enterotoxigenic Bacteroides fragilis cells and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes administering to a subject a Siphoviridae bacteriophage and lysing the enterotoxigenic Bacteroides fragilis cells by the Siphoviridae bacteriophage.
    Type: Application
    Filed: October 19, 2023
    Publication date: February 8, 2024
    Inventors: Seong Jun YOON, Jee Soo SON, In Hwang KIM, Hyoung Rok PAIK, Eun Kyoung OH, Soo Youn JUN, Sang Hyeon KANG
  • Patent number: 11844818
    Abstract: The present invention relates to a Myoviridae bacteriophage Aer-HYP-3 (Accession number: KCTC 13479BP) isolated from nature, which has the ability to kill Aeromonas hydrophila bacteria and has the genome represented by SEQ ID NO: 1, and to a method of preventing and treating a disease caused by Aeromonas hydrophila bacteria using a composition containing the same as an active ingredient.
    Type: Grant
    Filed: February 18, 2019
    Date of Patent: December 19, 2023
    Assignee: Intron Blotechnology, Inc.
    Inventors: Seong Jun Yoon, Soo Youn Jun, An Sung Kwon, Ji In Jung, Sang Hyeon Kang
  • Publication number: 20230331816
    Abstract: A method for preparing a porcine myoglobin includes: constructing a first plasmid containing genes for heme biosynthesis pathway enzymes; constructing a second plasmid containing a gene for Sus scrofa myoglobin MYG; constructing a first Escherichia coli production host containing the first plasmid and the second plasmid; and producing the porcine myoglobin by culturing the first Escherichia coli production host. A composition useful as a meat flavor and/or an iron supplement includes the porcine myoglobin prepared in accordance with the method.
    Type: Application
    Filed: January 9, 2021
    Publication date: October 19, 2023
    Inventors: Seong Jun YOON, Sang Hyeon KANG, Soo Youn JUN, An Sung KWON, Eun Ji LEE
  • Patent number: 11701398
    Abstract: A composition for preventing or treating an infection or disease caused by a pathogenic Escherichia coli includes a Podoviridae bacteriophage (Esc-COP-30) having an ability to lyse the pathogenic Escherichia coli and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by a pathogenic Escherichia coli includes administering to a subject a Podoviridae bacteriophage and lysing the pathogenic Escherichia coli by the Podoviridae bacteriophage.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: July 18, 2023
    Assignee: iNtRON Biotechnology, Inc.
    Inventors: Seong Jun Yoon, Jee Soo Son, In Hwang Kim, Hyoung Rok Paik, Hyun Joo Im, Hyun Jin Yu, Beom Seok Kim, Geun Woo Lee, Soo Youn Jun, Sang Hyeon Kang
  • Publication number: 20230212226
    Abstract: An antibacterial protein against Bacillus with the amino acid sequence as set forth in SEQ ID NO: 1 is disclosed. Also disclosed is a method of preparing an antibacterial protein against Bacillus. The method includes: culturing BL21-pBAD-BAL200 cells, the BL21-pBAD-BAL200 cells including a plasmid that comprising a sequence as set forth in SEQ ID NO: 2; inducing the expression of the antibacterial protein; and purifying the antibacterial protein.
    Type: Application
    Filed: March 6, 2021
    Publication date: July 6, 2023
    Inventors: Seong Jun YOON, Soo Youn JUN, Gi Mo JUNG, Jin Hee LEE, Sang Hyeon KANG
  • Patent number: 11679138
    Abstract: The present invention relates to a Myoviridae bacteriophage Vib-PAP-7 (Accession number: KCTC 13247BP) isolated from nature, which has the ability to kill Vibrio parahaemolyticus and has the genome represented by SEQ ID NO: 1, and a method for preventing or treating a disease caused by Vibrio parahaemolyticus using a composition containing the Myoviridae bacteriophage Vib-PAP-7 as an active ingredient.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: June 20, 2023
    Assignee: Intron Biotechnology, Inc.
    Inventors: Seong Jun Yoon, Soo Youn Jun, An Sung Kwon, Hyun Min Song, Eun Ji Lee, Sang Hyeon Kang
  • Patent number: 11679137
    Abstract: The present invention relates to Myoviridae bacteriophage Vib-PAP-4(Accession No. KCTC 13168BP), isolated from nature, which possesses ability to specifically kill Vibrio parahaemolyticus bacteria and has the genome represented by SEQ ID No: 1, and a method for preventing infection of Vibrio parahaemolyticus bacteria and treating infection of Vibrio parahaemolyticus baceteria, using a composition containing the bacteriophage as an effective ingredient.
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: June 20, 2023
    Assignee: Intron Biotechnology, Inc.
    Inventors: Seong Jun Yoon, Soo Youn Jun, An Sung Kwon, Hyun Min Song, Soon Hye Hwang, Sang Hyeon Kang
  • Publication number: 20230159599
    Abstract: The present invention relates to an antibacterial protein CDL200 with an antibacterial activity specific against Clostridioides difficile. More specifically, the present invention relates to an antibacterial protein CDL200 specific to Clostridioides difficile that may infect and cause disease in animals including humans, the antibacterial protein CDL200 being characterized by having the ability to specifically lyse the Clostridioides difficile and containing the amino acid sequence represented by SEQ ID NO: 1. In addition, the present invention relates to a pharmaceutical composition for treating an infection or disease caused by Clostridioides difficile, the composition containing the antibacterial protein CDL200 specific to Clostridioides difficile as an active ingredient.
    Type: Application
    Filed: March 31, 2021
    Publication date: May 25, 2023
    Inventors: Seong Jun Yoon, Jee Soo Son, In Hwang Kim, Cheol Ahn, Soo Youn Jun, Sang Hyeon Kang
  • Publication number: 20230074134
    Abstract: A method for preparing a soy leghemoglobin includes: constructing a first plasmid containing genes for heme biosynthesis pathway enzymes; constructing a second plasmid containing gene for Glycine max leghemoglobin LGB2; constructing a first Escherichia coli production host containing the first plasmid and the second plasmid; and producing the soy leghemoglobin by culturing the first Escherichia coli production host. A composition useful as a meat flavor and/or an iron supplement includes the soy leghemoglobin prepared in accordance with the method.
    Type: Application
    Filed: January 9, 2021
    Publication date: March 9, 2023
    Inventors: Seong Jun YOON, Sang Hyeon KANG, Soo Youn JUN, An Sung KWON, Eun Ji LEE
  • Publication number: 20230073947
    Abstract: A method for preparing a bovine myoglobin includes: constructing a first plasmid containing genes for heme biosynthesis pathway enzymes; constructing a second plasmid containing a gene for Bos taurus myoglobin MYG; constructing a first Escherichia coli production host containing the first plasmid and the second plasmid; and producing the bovine myoglobin by culturing the first Escherichia coli production host. A composition useful as a meat flavor and/or an iron supplement includes the bovine myoglobin prepared in accordance with the method.
    Type: Application
    Filed: January 9, 2021
    Publication date: March 9, 2023
    Inventors: Seong Jun YOON, Sang Hyeon KANG, Soo Youn JUN, An Sung KWON, Eun Ji LEE